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Abstract
Th17 cells are a subset of CD4+ T cells known to play a central role in the pathogenesis of
many autoimmune diseases, as well as in the defense against some extracellular bacteria
and fungi. However, Th17 cells are not believed to have a significant function against intra-
cellular infections. In contrast to this paradigm, we have discovered that Th17 cells provide
robust protection against Trypanosoma cruzi, the intracellular protozoan parasite that
causes Chagas disease. Th17 cells confer significantly stronger protection against T.
cruzi-related mortality than even Th1 cells, traditionally thought to be the CD4+ T cell sub-
set most important for immunity to T. cruzi and other intracellular microorganisms. Mecha-
nistically, Th17 cells can directly protect infected cells through the IL-17A-dependent
induction of NADPH oxidase, involved in the phagocyte respiratory burst response, and
provide indirect help through IL-21-dependent activation of CD8+ T cells. The discovery of
these novel Th17 cell-mediated direct protective and indirect helper effects important for
intracellular immunity highlights the diversity of Th17 cell roles, and increases understand-
ing of protective T. cruzi immunity, aiding the development of therapeutics and vaccines
for Chagas disease.
Author Summary
Chronic infection with the intracellular parasite Trypanosoma cruzi results in Chagas
disease, an illness endemic in more than 20 countries that leads to life-threatening car-
diac and gastrointestinal dysfunction. Although CD4+ Th1 cells are known to be protec-
tive against T. cruzi infection, less is known about the role of other CD4+ T cell subsets.
We demonstrate that CD4+ Th17 cells are also highly protective against T. cruzi infec-
tion, even outperforming Th1 cells in protection from T. cruzi-related death, despite the
standard conception that Th17 cells are only important in the defense against
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extracellular pathogens. The novel discovery that Th17 cells are significantly more pro-
tective than Th1 cells against T. cruzi infection has increased our understanding of the
advantageous immune responses for this major human pathogen, and may guide future
efforts toward vaccine development.
Introduction
Chronic infectionwith the protozoan parasite Trypanosoma cruzi results in Chagas disease, a
Neglected Tropical Disease currently affecting 8–11 million people worldwide and 300,000
people in the United States [1]. Humans usually acquire T. cruzi infection via reduviid insect
vectors, but infections also sometimes occur through vertical transmission, the ingestion of
contaminated food products, and the receipt of infected biological donations. The disease can
cause significant cardiac and gastrointestinal morbidity, but drug therapies are typically non-
curative and poorly tolerated [1]. The significant global burden of Chagas disease, coupled
with the inefficacyof available treatments, indicates a pressing need to develop novel therapeu-
tics, including preventative and/or therapeutic vaccines to induce protective T. cruzi immunity
in at risk individuals. The development of effective vaccines requires a more detailed under-
standing of the protective host immune responses against T. cruzi infection.
BecauseT. cruzi promiscuously infects both cells expressing MHC class II and cells express-
ing only MHC class I, CD8+ T cells are critical for protection against infection of all host targets
cells. However, CD4+ T cells also are needed for optimal protection [2]. CD4+ Th1 cells have
been shown to provide both systemic and mucosal protection against T. cruzi infection, consis-
tent with the well-established framework of Th1 cells being the CD4+ T cell subset most impor-
tant against intracellular pathogens [3,4]. Less is known about the role of other CD4+ T cell
subsets during T. cruzi infection.
More recently, studies have found a protective role for IL-17A, the major cytokine produced
by CD4+ Th17 cells, raising questions about the possibility of a protective role for Th17 cells
[5–7]. However, multiple subtypes of IL-17-producing cells exist, including αβ T cells, γδ T
cells, innate lymphoid cells, and even B cells in T. cruzi infection [8,9]. In addition, Th17 cells
have been shown to be involved in autoimmunity [10–12]. Thus, it remained unclear from
these studies of global IL-17A deficiencywhether Th17 cells specifically play a protective or
pathologic role in T. cruzi immunity. Although Th17 cells are now known to protect against
certain extracellular bacteria and fungi [13–16], they are not thought to have a significant func-
tion in intracellular immunity.
To investigate the specific effects of different CD4+ T cell subsets in T. cruzi infection, we
generated T cell receptor transgenic (TS-CD4-Tg)mice with CD4+ T cell receptors that are
specific for p7, an immunodominant epitope encoded by the T. cruzi trans-sialidase, a highly
conserved virulence factor and potential vaccine target (S1 and S2 Figs) [17–20]. Using CD4+
T cells from these mice, we were able to generate parasite-specific Th1 and Th17 cells in vitro.
These cells were used for studies in vivo using adoptive transfer experiments, and in vitro using
CD8+ T cell activation and macrophage infection assays. Through these experiments, we found
that Th17 cells confer robust protection against T. cruzi infection, even surpassing that pro-
vided by Th1 cells, through both direct and indirect protective effects.
Th17 Cells and Trypanosoma cruzi Immunity
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Results
Th17 cells provide stronger protection from T. cruzi-related mortality
than Th1 cells
To study the roles of Th1 cells versus Th17 cells in vivo, in vitro-differentiated TS-CD4-Tg Th1
or Th17 cells were adoptively transferred with naïve polyclonal CD8+ T cells into RAG KO
mice, which were then challenged subcutaneously with T. cruzi (S3 Fig, Fig 1A and 1B). We
confirmed the persistence of these transferred cells (S4 Fig). As expected, control RAG KO
mice (no T cell transfer) did not survive the challenge, and nearly all mice receiving CD8+ T
cells alone also succumbed to infection. Consistent with previous studies supporting a protec-
tive function for Th1 cells against T. cruzi, mice receiving co-transfer of Th1 cells and CD8+ T
cells exhibited lower blood parasite burdens and improved long-term survival.However, sur-
prisingly, mice receiving co-transfer of Th17 cells and CD8+ T cells experienced the strongest
protection, as indicated by the lowest blood parasite burdens and highest survival rates (100%
long term) of any group. This represented significantly improved protection even compared to
mice receiving Th1 cells (p<.001 comparing Th17 and CD8+ T cells to Th1 and CD8+ T cells,
Fig 1A and 1B).
Fig 1. Th17 cells provide better protection in vivo than Th1 cells. Polyclonal CD8+ T cells were transferred into RAG KO mice along
with either Th1 or Th17 T. cruzi-specific T cells (>10/group). Mice were then systemically challenged with T. cruzi. (A) Parasitemia counts
19 days post-infection demonstrate that co-adoptive transfer of Th17 cells resulted in better control of infection than co-adoptive transfer of
Th1 cells ***p<0.001, **p<0.01, *p<0.05 by two-tailed Student t test. (B) All groups receiving CD8+ T cells were significantly protected
compared to no adoptive transfer. Co-adoptive transfer of Th17 cells led to 100% long-term survival that was significantly higher than
survival in all other groups.***p<0.001 by Mantel-Cox log-rank test. (C) T-bet KO Th17 cells resulted in decreases in parasite load
comparable to WT Th17 cells when transferred into RAG KO mice (>7/group) with CD8+ T cells. **p<0.01 by two-tailed Student t test. (D)
T-bet KO Th17 cells resulted in equivalent long-term protection from mortality compared to WT Th17 cells.
doi:10.1371/journal.ppat.1005902.g001
Th17 Cells and Trypanosoma cruzi Immunity
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Because our Th17 cell cultures also contained undifferentiated cells not expressing the clas-
sical Th17 markers RORγt or IL-17 (S3C Fig), we sought to confirm that the impressive protec-
tion was truly a Th17 cell-mediated effect, and not attributable to another cell type present in
the Th17 cell cultures. To do so, we used cell purification kits to obtain>90% purity of IL-17+
cells from our Th17 cell cultures (S5A Fig). Co-transfer of these cells with polyclonal CD8+ T
cells into RAG KO mice resulted in sustained Th17 cell responses and similar activation of the
CD8+ T cells (S5B and S5C Fig). Even more importantly, the transfer of highly purified IL-17+
T cells resulted in protection from T. cruzi (S5D and S5E Fig), confirming that bona fide Th17
cells provide protection against this parasite. We also tested polyclonal T. cruzi-specificTh17
cells, which were generated by stimulating wild-typeCD4+ T cells with dendritic cells pulsed
with whole parasite lysate antigens under Th17-skewing conditions (S6A Fig). We found that
polyclonal Th17 cells, which better model a Th17 cell response that could arise in vivo, also
result in significantly lower parasitemia and 100% long-term survival when given with CD8+ T
cells (S6B–S6D Fig).
Furthermore, Th17 cells have been reported to maintain plasticity and revert to Th1 pheno-
types in vivo [21–23], raising another important consideration. Indeed, although Th17 cells
persisted after transfer, as indicated by sustained production of IL-17, a small percentage of in
vitro-biased Th17 cells expressed IFN-γ (S3C Fig), and some Th1 cells emerged from Th17
cells in vivo (S4A and S4C Fig). Therefore, we asked whether the IFN-γ expressed by a small
subset of Th17 cells, or the trans-differentiation of Th17 cells into Th1 cells after transfer, was
responsible for the protective effects. To answer this question, we generated T-bet KO
TS-CD4-Tgmice lacking T-bet, the transcription factor that drives Th1 differentiation and
IFN-γ production (T-bet KO TS-CD4-Tg). Using CD4+ T cells from these mice, we made T.
cruzi-specificT-bet KO Th17 cells, which are unable to adopt the Th1 phenotype.We gave
RAG KO mice T-bet KO TS-CD4-Tg Th17 cells and polyclonal CD8+ T cells, and infected
them with T. cruzi. CD4+ T cells recovered from recipient mice 9 and 101 days after infection
confirmed that the transferred T-bet KO Th17 cells were veritable Th17 cells, as they did not
produce IFN-γ in vivo, but maintained high levels of IL-17A expression (S7A and S7B Fig).
Mice receivingWT or T-bet KO Th17 cells were similarly protected, with significantly
decreased parasite burdens compared to control and 100% long-term survival (Fig 1C and 1D).
The persistence of Th17 cells and their protective effects could be detectedmore than three
months after initial infection (S7C Fig), providing further evidence that a stable Th17 cell
response to T. cruzi is possible, and that there is no requirement for Th1 cells or any other
IFN-γ+ CD4+ T cells for robust T. cruzi immunity.
IL-17A induces NADPH oxidase function to provide direct protection in
vitro
To investigate mechanisms of direct protection against T. cruzi infection by Th17 cells, we
infectedmurine peritoneal exudate macrophages (PEM) with T. cruzi trypomastigotes in vitro
and added Th1 or Th17 cells for two days. In the absence of T cells, high-level parasite infection
occurred. The addition of either Th1 cells or purified IFN-γ alone significantly reduced num-
bers of cells that became infected after two days. Th1 cells are known to prime macrophage
activation for the killing of intracellular microorganisms through the secretion of IFN-γ. Con-
sistent with this, a neutralizing antibody directed against IFN-γ reversed the effects of Th1-me-
diated protection (Fig 2A–2C) [24]. The addition of Th17 cells to the cultures also reduced the
parasite burden among infectedmacrophages, indicating that Th17 cells are able to directly
protect cells against T. cruzi infection. This effect could be recapitulated by replacing Th17 cells
with purified IL-17 cytokine, or abrogated by adding an IL-17A-neutralizing antibody,
Th17 Cells and Trypanosoma cruzi Immunity
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indicating that the protection is mediated by the IL-17 produced by Th17 cells. Although
Th17-derived IL-17A is known to recruit neutrophils and enhance inflammation in extracellu-
lar infections, a direct intracellular protective effect has not been previously reported.
We confirmed previous studies showing that Th1 cells, through the production of IFN-γ,
induce macrophage iNOS to produce nitric oxide [25], the mechanism underlying the killing
of intracellular pathogens. However, NO was not induced by Th17 cells (Fig 2D), and although
the addition of the iNOS inhibitor N6-(1-Iminoethyl)-L-lysine (L-NIL) reversed Th1-mediated
protection, it had no effect on Th17-mediated protection (Fig 2E). These data indicate that the
direct protection provided by Th17 cells operates independently of NO generation.
Similar to NO-mediated protection, ROS can also inhibit the growth of intracellular patho-
gens in neutrophils and macrophages [26]. IL-17A has been reported to induce production of
ROS in endothelial cells, but it was unknownwhether the cytokine could induce ROS in other
cells [27]. We hypothesized that Th17 cells could also induce ROS production in macrophages,
and that the induction of ROS was necessary for IL-17-mediated direct protection. To test our
hypothesis, we infected bone marrow-derivedmacrophages (BMDMs) generated fromWT
and gp91phox KO mice. The latter are genetically deficient in a critical subunit of the NADPH
oxidase, resulting in a defective phagocyte respiratory burst response. Following infection of
these cells, we treated themwith IFN-γ or IL-17A for 48 hours. The gp91phox deficiencydid not
affect the induction of NO (Fig 2F). In both infectedWT and gp91phox KO BMDM, IFN-γ
Fig 2. Th17 cells can inhibit T. cruzi intracellular growth in macrophages in vitro by inducing NADPH oxidase via IL-17A. PEMs
were infected with trypomastigotes for 3 hours (MOI = 5). T. cruzi-specific TCR Tg Th1 or Th17 cells were then added to macrophages
1:25. Two days later, slides were Giemsa stained and intracellular parasites counted microscopically. Th1 and Th17 cells (A), as well as
IFN-γ or IL-17A alone (B) were able to decrease the number of infected macrophages. *p<0.001 compared to medium alone by two-tailed
Student t test. (C) Neutralizing antibodies directed against IFN- γ or IL-17A were able to abolish the direct protection provided by Th1 and
Th17 cells, respectively. (D-E) The effects of the iNOS inhibitor L-NIL on Th1- and Th17-induced NO production and T. cruzi protection are
shown. **p<0.001 by two-tailed Student t test. (F+G) BMDMs from wild type (WT) and gp91phox KO mice were infected with T. cruzi for 3
hours (MOI = 10), then cytokines IFN-γ and IL-17A were added. Two days later, NO was measured (F) and intracellular parasites were
enumerated (G). **p<0.001 by two-tailed Student t test. These results were reproduced in multiple experiments.
doi:10.1371/journal.ppat.1005902.g002
Th17 Cells and Trypanosoma cruzi Immunity
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treatment induced NO production, but IL-17A did not (Fig 2F). In WT BMDM, both IFN-γ
and IL-17A protected against infection and intracellular growth of T. cruzi. Deficiencyof the
gp91phox subunit of NADPH oxidase had no effect on IFN-γ-mediated protection, but reversed
IL-17A-mediated protection, indicating that functional NADPH oxidase is required for this
mechanism, and suggesting the involvement of ROS generated during the respiratory burst
(Fig 2G).
IL-17A does not mediate protection by Th17 cells in vivo
Given our findings concerning IL-17-mediated protection in vitro, we asked whether IL-17A
was also responsible for the protection observed in vivo. We first neutralized IL-17A in RAG
KO mice reconstituted with Th17 cells and polyclonal CD8+ T cells by injection of a monoclo-
nal anti-IL-17A antibody previously shown to reverse IL-17A function in vivo [28,29]. Neutral-
izing IL-17A had no effect on parasitemia levels or survival percentages in these mice (Fig 3A
and 3B). We also overexpressed IL-17A in RAG KO mice receiving polyclonal CD8+ T cells
alone using a recombinant IL-17A-producing adenovirus (IL-17A AdV). Althoughmice
injectedwith IL-17A AdV had markedly higher serum levels of IL-17A (28 ng/ml ± 16 in IL-17
AdV sera versus<0.02ng/ml in control AdV sera), overexpression of IL-17A alone was not
enough to replace Th17 cells, and did not protect mice also receiving CD8+ T cells (Fig 3C and
3D). Overall, these results indicate that IL-17 is dispensable for the major in vivo protective
effects induced by Th17 cells, despite being the major Th17 cytokine implicated in previous
reports on Th17-based protection and pathology. Therefore, in T. cruzi infection, Th17 cells
must function through an IL-17-independentmechanism to protect.
Helper effects on CD8+ T cells execute Th17-mediated protection in vivo
To discriminate between direct protective versus indirect T helper effects, we studied protec-
tion provided by Th17 cells transferred alone or with polyclonal CD8+ T cells. CD8+ T cells
were needed for optimal Th17-mediated protection (Fig 4A and 4B), indicating Th17 helper
effects for CD8+ T cells were most important in vivo. However, the mechanism of Th17 helper
effects on CD8+ T cells could be due to Th17 cells directly instructing these cells, or Th17 cells
indirectly affecting these cells via the activation of antigen-presenting cells. To distinguish
between these potential mechanisms, naïve polyclonal CD8+ T cells were stimulated with sub-
optimal α-CD3 in vitro. Th17 cells and/or immature dendritic cells (DCs) were added to these
cultures to provide potential co-stimulatory help. In the absence of Th17 cells, CD8+ T cells
exhibited progressive degrees of proliferation with sub-optimal α-CD3 stimulation and
increasing doses of DC (Fig 4C), as detected by dilution of the cell staining dye CFSE. However,
nearly 100% of CD8+ T cells proliferated maximally when Th17 cells were introduced, even in
the absence of DC. These data indicate that Th17 cells directly and strongly enhance the activa-
tion of naïve CD8+ T cells.
Th17 cells exert T helper effects on CD8+ T cells via IL-21
In addition to increasing the proliferation of CD8+ T cells, Th17 cells also induced these cells to
increase the expression of surface CD44 (a marker of activated T cells), the effector cytokine
IFN-γ, and the chemokineMIP-1α, indicating an activated state of CD8+ T cells (Fig 4D).
These helper effects on CD8+ T cells were also detectable using supernatants (SN) from acti-
vated Th17 cells, implicating soluble factors (Fig 4D). However, consistent with our previous in
vivo results, neutralization of IL-17A did not prevent the Th17-mediated activation of CD8+ T
cells in vitro (Fig 4D). By co-culturing sub-optimally stimulated CD8+ T cells with individual
purified Th17 cytokines, we discovered that IL-21 alone recapitulated this potent help,
Th17 Cells and Trypanosoma cruzi Immunity
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inducing a state of CD8+ T cell activation similar to that seen with the addition of Th17 cells or
Th17 cell SNs (Fig 4E). We confirmed that our Th17 cells produced significant amounts of IL-
21, while the Th1 cells did not (Fig 4F, S3F Fig).
In vitro assays demonstrated that IL-21R KO CD8+ T cells are unable to be activated by
Th17 cell SNs in the samemanner as WTCD8+ T cells (Fig 5A), confirming the IL-21 signaling
requirement for Th17-mediated protection. To test these results in vivo, we transferred Th17
cells into RAG KO mice with eitherWT or IL-21R KO CD8+ T cells, and challenged the mice
with T. cruzi. Recovered spleen cells frommice receiving IL-21R KO CD8+ T cells with Th17
cells had impaired responses to T. cruzi TS antigen/peptide stimulation (Fig 5B). Furthermore,
only mice receiving Th17 cells withWT CD8+ T cells were able to control infection. Although
mice givenWT CD8+ T cells reduced parasitemia after day 15, parasitemia levels steadily
Fig 3. IL-17A alone is not responsible for the Th17-mediated enhanced protective effects. (A-B) T. cruzi-specific Th17 cells were co-
transferred with CD8+ T cells into RAG KO mice (5/group) prior to T. cruzi challenge. Neutralizing anti-IL-17A or control IgG1 antibodies
were injected intraperitoneally every 48 hours. IL-17A neutralization did not reduce protection as measured by both parasitemia (A) and
survival (B). *p<0.001 by two-tailed Student t test, **p<0.01 by log-rank test compared with negative controls. (C-D) Polyclonal CD8+ T
cells were transferred intravenously (i.v.) into RAG KO mice prior to T. cruzi infection. Either control AdV or IL-17 AdV was injected 1 day
prior to infection and 7 days post-infection at 5x109 PFU i.v. Protection was measured by parasitemia 18 days post-infection (C) and
survival (D).
doi:10.1371/journal.ppat.1005902.g003
Th17 Cells and Trypanosoma cruzi Immunity
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increased in mice receiving IL-21R KO CD8+ T cells (Fig 5C). As a result of this failed protec-
tion, all mice receiving IL-21R KO CD8+ T cells succumbed to infectionwhile 100% of mice
receivingWT CD8+ T cells with Th17 cells survived long-term (Fig 5D). These studies clearly
demonstrate that Th17-mediated protection in vivo operates through the secretion of IL-21,
and the resulting indirect T helper effects on CD8+ T cells.
Th17 cells result in greater numbers of CD8+ T cells, higher levels of T-
bet expression and stronger antigen-specific responses than Th1 cells
Given the improved protection afforded by Th17 over Th1 helper cells, we next explored the
mechanisms responsible for the reason Th17-induced CD8+ T cells can control infection better
than Th1-induced CD8+ T cells. Recovered spleen cells from RAG KO mice reconstituted with
CD8+ T cells and Th1 or Th17 cells prior to T. cruzi challenge demonstrated that mice receiv-
ing Th17 cells had greater expansion of CD8+ T cells than mice receiving Th1 cells (Fig 6A). In
Fig 4. T. cruzi-specific Th17 cells provide T helper effects and directly activate CD8+ T cells through a soluble mediator. (A) Th17
cells required co-adoptive transfer with polyclonal CD8+ T cells to confer optimal immunity as measured by parasite burden. **p<0.01,
***p<0.001 by two-tailed Student t test. (B) Th17 cells transferred alone were not able to protect mice from T. cruzi-related death,
indicating that Th17 cells protect through helper effects on CD8+ T cells. **p<0.01 by Mantel-Cox log-rank test. (C) CFSE-labeled,
polyclonal CD8+ T cells were sub-optimally activated with plate-bound α-CD3 (1 μg/ml) and increasing numbers of dendritic cells. CD8+ T
cells were cultured with or without Th17 cells for 5 days. Proliferation was measured by CFSE dilution. (D) CD8+ T cells were sub-optimally
activated with α-CD3 as in C (without added dendritic cells), in the presence of Th17 cells, Th17 SNs or Th17 cells plus IL-17A neutralizing
antibody. CD8+ T cell proliferation, CD44 expression and MIP-1α/IFN-γ production were measured 5 days later by Flow Cytometry and ICS
and shown as fold increases compared with α-CD3 activation alone. (E) Purified Th17 cytokines were individually added to sub-optimally α-
CD3 activated CD8+ T cells and markers of activation were analyzed 5 days later. (F) High levels of IL-21 could be detected by ELISA in
Th17 cell SNs, but not in Th1 cell SNs. Representative results from multiple experiments are shown.
doi:10.1371/journal.ppat.1005902.g004
Th17 Cells and Trypanosoma cruzi Immunity
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addition, CD8+ T cells primed by Th17 cells either in vivo (Fig 6B) or in vitro (Fig 6C)
expressed higher levels of T-bet compared with Th1-primed cells, which has been associated
with higher cytotoxic activity and IFN-γ production [30,31]. IFN-γ ELISPOT and ICS assays
comparing spleen cells recovered from Th1- or Th17-transferredmice demonstrated that mice
receiving Th17 cells also had>6-fold stronger total spleen cell responses to T. cruzi TS antigen,
and>10,000-fold greater frequencies of antigen-specificCD8+ T cells than mice receiving Th1
cells (Fig 6D and 6E). Overall, these results indicate that both quantitative and qualitative dif-
ferences distinguish Th1- and Th17-induced CD8+ T cells.
Fig 5. Th17 cell-derived IL-21 can help expand and activate protective CD8+ T cells. (A) WT or IL-21R KO CD8+ T cells were sub-optimally
stimulated with plate-bound α-CD3 as in Fig 4C and 4E. ICS assays indicated the addition of Th17 cell SNs could help activate WT CD8+ T cells
but not IL-21R KO CD8+ T cells. Shown are fold increases compared to WT or IL-21R KO CD8+ T cells cultured with sub-optimal α-CD3 alone,
without Th17 cell SNs. (B) Total spleen cells (TSCs) recovered from infected RAG KO mice adoptively transferred with Th17 cells and IL-21R KO
CD8+ T cells had diminished responses to TS stimulation compared to mice receiving Th17 cells and WT CD8+ T cells prior to challenge, as
measured by IFN-γ ELISPOT. (C) Mice transferred with Th17 cells (n = 4) and IL-21R KO CD8+ T cells (n = 8) were unable to control infection, as
indicated by increasing parasitemia over time. **p<0.01 by two-tailed Student t test. (D) Transfer of IL-21R KO CD8+ T cells failed to protect mice
from T. cruzi-mortality. *** p<0.001 by Mantel-Cox log-rank test.
doi:10.1371/journal.ppat.1005902.g005
Th17 Cells and Trypanosoma cruzi Immunity
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Th17 cells also provide robust helper effects to CD8+ T cells and B cells
in immunocompetent mice
In order to test whether Th17 cells can have similar in vivo helper effects for CD8+ T cells in a
physiological setting, where millions of CD4+ and CD8+ T cells of diverse specificities co-
exist, we adoptively transferred immunocompetentWT BALB/c mice with TS-CD4-Tg Th1
or Th17 cells, then challenged these mice with highly virulent blood-form trypomastigotes.
Total splenic cells and purified CD8+ T cells recovered frommice receiving Th17 cells con-
tained 3- to 4-fold higher frequencies of antigen-specific total spleen cells (Fig 7A) and CD8+
T cells (Fig 7B) compared with mice given Th1 cells, consistent with our findings in RAG KO
mice. These latter results indicate that superior Th17 helper effects were reproducible in a
physiologic setting. In addition,WT BALB/c mice receiving adoptive transfer of either Th1 or
Th17 cells developed higher titers of TS-specific antibodies than mice not receiving any cell
transfer, indicating that, in addition to their robust helper effects on critically protective CD8+
T cells, Th17 cells also provide substantial help to T. cruzi-specific antibody-secretingB cells
(Fig 7C and 7D).
Fig 6. Enhanced protection by Th17 cells involves more potent qualitative and quantitative helper effects for the development of
T. cruzi-specific CD8+ T cells. RAG KO mice were adoptively transferred with polyclonal CD8+ T cells and Th1 or Th17 cells and then
infected systemically with T. cruzi. (A) Greater absolute numbers of CD8+ T cells were recovered from mice co-adoptively transferred with
Th17 cells at 7 days post-infection. (B) The mean fluorescence intensity (MFI) of T-bet expression in these same CD8+ T cells was
increased over mice receiving CD8+ T cells alone or CD8+ T cells with Th1 cells, as measured by ICS. (C) Co-culture of sub-optimally
stimulated CD8+ T cells with activated Th17 cell SN in vitro also induced higher T-bet expression than co-culture with Th1 cell SN. (D-E)
Antigen-specific total and CD8+ T cell responses were studied 7 days post-challenge by IFN-γ ELISPOT (D) and intracellular cytokine
staining (E), respectively. Similar results were detected in multiple experiments.
doi:10.1371/journal.ppat.1005902.g006
Th17 Cells and Trypanosoma cruzi Immunity
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T. cruzi-reactive Th17 cells can be induced in vivo by vaccination
Despite being highly protective, Th17 cells are not the predominant natural CD4+ T cell
response to T. cruzi infection.However, Th17 cells could be targeted for induction by vaccina-
tion. In the past, we have successfully inducedT. cruzi-specificTh1 cells in vivo by vaccinating
wild-typemice with recombinant TS protein (rTS) and the TLR-9 agonist CpG as an adjuvant
[19]. To induce Th17 cells, we vaccinated TS-CD4-Tgmice intramuscularly with rTS com-
bined with the TLR-1/2 agonist and Th17-skewing adjuvant Pam3CSK4 instead [32], and com-
pared these to mice receiving rTS with CpG. T. cruzi-reactive Th1 responses could be detected
by IFN-γ ELISPOT assay among splenic CD4+ T cells recovered from TS-CD4-Tgmice vacci-
nated with rTS and CpG, but not frommice vaccinated with rTS and Pam3CSK4 (S8A Fig).
On the contrary, the use of Pam3CSK4 as an adjuvant induced the generation of T. cruzi-reac-
tive Th17 cells detectable by IL-17A ELISPOT, while the use of CpG as an adjuvant did not
(S8B Fig). These data indicate that endogenous,T. cruzi-specificTh17 cells can be induced in
Fig 7. Th17 cells also provide robust helper effects to CD8+ T cells and B cells in immunocompetent mice. Total spleen cells (A)
and purified CD8+ T cells (B) recovered from WT BALB/c mice receiving TS-CD4-Tg Th17 cell adoptive transfer developed 3- to 4-fold
higher levels of IFN-γ producing T. cruzi-specific T cells detectable responses upon stimulation with either p7 or whole TS antigen. (C-D)
Adoptive transfer of TS-CD4-Tg Th1 cells resulted in an approximately 3-fold increase in antibody titers, and adoptive transfer of Th17 cells
resulted in an approximately 9-fold increase, as measured by endpoint titers.
doi:10.1371/journal.ppat.1005902.g007
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vivo by vaccination when the appropriate biasing adjuvants for promoting Th17 cell responses
are used.
Discussion
Recent studies demonstrating that IL-17 confers resistance against T. cruzi infection raised the
possibility that Th17 cells could play a protective role, although Th1 cells are typically consid-
ered the most important CD4+ T cell subset for immunity against T. cruzi as well as other intra-
cellular organisms. Th17 cells are known to be important for protection against a number of
extracellular bacteria and fungi [13,33,34], but are not believed to function significantly against
intracellular pathogens. In addition to the protective roles of Th17 cells in the human immune
system, Th17 cells are also known to drive pathology in many autoimmune and inflammatory
diseases, including multiple sclerosis and rheumatoid arthritis [8]. Previous studies demon-
strating a protective function for IL-17 utilizedmodels of global IL-17 deficiency [5,6], preclud-
ing any specific interpretation of the role of Th17 cells, as IL-17 is produced by multiple innate
and adaptive cellular sources. Therefore, it remained unclear whether Th17 cells were protec-
tive or pathological during T. cruzi infection.
Our lab recently generated a line of T cell receptor transgenic mice with CD4+ T cells spe-
cific for a single immunodominant epitope of the trans-sialidase virulence factor; immune
responses directed against this immunodominant antigen can be highly protective. This critical
reagent has greatly advanced our ability to fully explore the roles of various CD4+ T cell subsets
in T. cruzi infection.We studied parasite-specific Th1 and Th17 cells in vivo in adoptive trans-
fer experiments and in vitro using macrophage infection assays and CD8+ T cell activation
assays. With these studies, we have created strong evidence that Th17 cells can orchestrate a
powerful protective response to T. cruzi infection: 100% of RAG KO mice co-transferred with
Th17 cells and CD8+ T cells survives a normally lethal T. cruzi challenge.
Mechanistically, we discovered that through the secretion of IL-17A, Th17 cells trigger the
function of NADPH oxidase to provide direct protection to infected cells. A previous report
suggests that IL-17Amay function to retain T. cruziwithin the endosomes of host cells [35].
Our discovery that IL-17A acts through NADPH oxidase, involved in the phagocyte respira-
tory burst, indicates that this cytokinemay direct synergisticmechanisms to promote immu-
nity in infectedmacrophages. NADPH oxidase functions in the cell to produce superoxide and
other ROS; these reactive products could protect against T. cruzi by directly killing intracellular
pathogens or by functioning as signalingmolecules to activate other protective pathways.
Future investigations should focus on elucidating the detailedmechanisms of protection and
the signaling events involved in IL-17 receptor triggering of NADPH oxidase activity.
In addition, we demonstrated that the major mechanism of protection provided by Th17
cells in vivo is the help provided to critical CD8+ T cells, the major effector cells responsible for
T. cruzi immunity, by the secretion of IL-21. IL-21 is known to have several effects on CD8+ T
cell function, including the enhancement and maintenance of antigen-specific proliferation
and function, particularly during chronic infection [30,31,36,37]. Therefore, Th17-primed
(and thus IL-21-primed) CD8+ T cells may offer several advantages over Th1-primed CD8+ T
cells in the course of T. cruzi infection,making Th17 cells a highly relevant CD4+ T cell subset
to target during the development of vaccines for Chagas disease, and perhaps for other patho-
gens. Additional experiments will investigate whether Th17 help for CD8+ T cell activation
through IL-21 can generate more antigen-specific cells with more broadly reactive epitope
specificity than Th1 priming.
Interestingly, in our model, neutralization of IL-17 had no detrimental effects for mice
receiving Th17 cell transfer, although previous studies found that IL-17-deficient animals were
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more susceptible to T. cruzi infection [5–6]. Our findings that IL-17 alone can protect infected
macrophages in vitro are consistent with these previous reports that IL-17 has protective func-
tions. However, in vivo, CD8+ T cells are the major effector cells protective against T. cruzi
infection, and through the secretion of IL-21, Th17 cells efficiently promote a robust CD8+ T
cell response independent of IL-17. In the context of this strong CD8+ T cell activation, the
directly protective effects of IL-17 may be secondary or dispensable. In our adoptive transfer
experiments, in vitro-differentiated Th17 cells representing an adaptive immune response are
given to mice prior to T. cruzi infection, to provide a convenient model for studies of a vaccine-
induced protective state. Importantly, we have demonstrated that Th17 cells can indeed be
induced by vaccination in TS-CD4-Tgmice using Th17-skewing adjuvants.
Taken altogether, these data advance our knowledge of the protective CD4+ T cell responses
to T. cruzi infection, and illuminate the relevant T cell subsets and cytokine profiles to target in
vaccination strategies. This novel understanding advances the goal of developing of a human
Chagas vaccine, which could prevent 12,000 deaths per year and evenmore instances of dis-
ability. More broadly, these studies provide the first clear and strong evidence that Th17 cells
can function significantly in intracellular as well as extracellular immunity, suggesting that
Th17 cells may be an advantageous immune response to similar pathogens, and indicating the
need for a revised Th1/Th2/Th17 framework. Given their newly identified role in intracellular
immunity and their potent effects on CD8+ T cells, Th17 cells may prove to have a more
diverse influence on the host immune response than previously thought. With increased
understanding of their many roles and the mechanisms underlying their desired protective
effects, Th17 cells could become an attractive target for host-directed therapies against various
infectious pathogens.
Materials and Methods
Ethics statement
All animal studies were conducted in accordance with the “Guide for the Care and Use of Lab-
oratory Animals” manual published by the National Research Council and endorsed by the
Assessment and Accreditation of Laboratory Animal Care (AAALAC), with the approval of
the Institutional Animal Care and Use Committee (IACUC)/Animal Care Committee (ACC),
under protocol #1106, assigned by Saint Louis University’s IACUC. All mice were maintained
in an AAALAC accredited facility at Saint Louis University.
Mice
BALB/c mice (NCI Charles River Laboratories, Frederick, MD), RAG KO mice (The Jackson
Laboratory, Bar Harbor, ME), and T. cruzi trans-sialidase amino acids 57–74 (TSaa57-74)-spe-
cific TCR transgenic mice on the Thy1.1 BALB/c background (TS-CD4-Tg, generated in the
Hoft laboratory) were used throughout this study. Tbx21-/-mice (The Jackson Laboratory, Bar
Harbor, ME) and IL-21R KO BALB/c mice (provided by Dr. Manfred Kopf, ETH Zurich) were
used to generate CD4+ and CD8+ T cells for adoptive transfer experiments. C57BL/6 wild type
mice (WT, NCI Charles River Laboratories, Frederick,MD) and B6.129S6-Cybbtm1Din/J mice
lacking the gp91phox catalytic subunit of NADPH oxidase (gp91phox KO, The Jackson Labora-
tory, Bar Harbor, ME) were used to generate bonemarrow-derivedmacrophages. Mice were
housed under specific pathogen free conditions. Sample sizes were based on previous experi-
ence, and sample size calculations were approved by the Saint Louis University Animal Care
Committee and follow AAALAC guidelines and recommendations. All studies included age-
and gender-matched groups. Although no formal blinding was done, all key experimental
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results were reproducible in multiple experiments and when conducted by different individuals
in the laboratory.
Parasites and challenges
The Tulahuèn strain of T. cruziwas passaged through BALB/c mice and Dipetalogaster maxi-
mus insects. Blood form trypomastigotes (BFT) were collected from infectedmice and used for
systemic challenges in BALB/c mice. Culture-derivedmetacyclic tryptomastigotes (CMT) were
generated as described [38] and used for in vitro studies and for the systemic challenges of
RAG KO BALB/c mice. Systemic challenges were performed by subcutaneous (s.c.) injection of
5,000 BFTs or CMTs re-suspended in in 100 μl phosphate buffered saline (PBS). In vitro infec-
tions of macrophages were performed by culturing cells with CMT at 5–10 multiplicities of
infection (MOI).
Murine vaccinations
We used a DNA vaccine encoding the consensus TS enzymatic domain as describedpreviously
[19], originally provided by Dr. Maurício M. Rodrigues (São Paulo, Brazil). BALB/c mice were
immunized with 100 μg TS-DNA or control DNA intramuscularly (i.m.).We also vaccinated
mice intranasally (i.n.) with 50 μg recombinant trans-sialidase plus 10 μg CpG-containing oli-
godeoxynucleotides (ODN) 1826 (Invivogen, San Diego, CA). For dendritic cell (DC) vaccines,
splenic DCwere isolated after intraperitoneal (i.p.) injection of BALB/c mice with 5x106 B16
cells expressing Flt-3 ligand as previously described [39]. DCwere induced to mature in vivo
with 2 μg lipopolysaccharide given intravenously (i.v.) and harvested from spleens 16 hours
later using α-CD11cmicrobeads (Miltenyi Biotec, Inc., Auburn, CA). The purity and activation
status of DCwere determined by staining for CD11c, CD86 and MHC class II, and>90% pure
CD11c+ DCwere obtained. DCwere pulsed with 100 μg/ml TS peptides p7 (TSaa57-74, aa
sequence KVTERWHSFRLPALVNV) and/or 100 μg/ml TSKd1 (TSaa359-367, aa sequence
IYNVGQVSI) for 90 minutes at 37°C, washed and then injected i.v. into BALB/c mice (1x106
cells/mouse). To induce Th1 and Th17 cells in vivo, TS-CD4-Tgmice were anesthetized with
Ketamine/Xylazine, and 50 μg of rTS protein mixed with either 50 μg CpG or 50 μg Pam3Cys-
SerLys4 (Invivogen, San Diego, CA) re-suspended in 100 μl volumes of PBS were injected into
the left and right tibialis anterior muscles (50 μl per side).
Production of TS-specific CD4+ T cell clones
We screened various 18mer peptide sequences from the consensus catalytic region of TS using
IFN-ɣ ELIPSOT assays and identified an immunodominant I-Ad-restricted CD4+ T cell epi-
tope (p7, TSaa57-74, aa sequence KVTERWHSFRLPALVNV, S1 Fig, S1 Table). We prepared
T cell clones as describedpreviously [2]. Briefly, we immunizedmice with TS DNA 3 times,
each 2 weeks apart. Two weeks after the third immunization, spleen cells were harvested and
CD4+ T cells purifiedwith α-CD4microbeads (Miltenyi Biotec, Auburn, CA). T cells were
stimulated in vitro with recombinant TS protein or irradiated spleen cells pulsed with TSaa57-
74 (p7) in the presence of 10 U/ml IL-2. After 2 cycles of antigen stimulation and IL-2 expan-
sion, T cell cloning was performed by limiting dilution.
Generation of TS-CD4-Tg mice
We amplified clonal TCR-α and TCR-β chain cDNA from a TS p7-reactive T cell clone. We
then subcloned these TCR-α (Vα2) and TCR-β (Vβ8.2) sequences into a CD2 vector
(VAhCD2 vector, kindly provided by Dr. Richard DiPaolo and Dr. D. Kioussis) [40]. We
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digested and gel purified the TCR DNA fragments and injected them into the pronucleus of
C57BL/6 x BALB/c fertilized eggs, with the help of Dr. MikeWhite at Washington University,
Saint Louis,MO. We screenedweanlings by PCR for the TCR chains Vα2 and Vβ8.2.We back-
crossed TCR Tg mice onto a congenic Thy1.1+ BALB/c background to generate TCR trans-
genic peripheral T cells capable of recognizing the I-Ad-restricted p7 epitope. Subsequent
generations of TCR Tg mice were screened by flow cytometry for Vβ8.2 surface expression on
peripheral T cells or MHC II:KVTERWHSFRLPALVNV tetramer staining (NIH Tetramer
Core Facility, EmoryUniversity, Atlanta, GA).
Generation of Th1 and Th17 cells
Trans-sialidase-specific T cell lines were derived from naïve TS-CD4-Tgmice. Spleens from
naïve Thy1.1+ transgenic mice were harvested, and CD4+ T cells were purified by positive
selection using α-CD4microbeads (Miltenyi Biotec, Auburn, CA). The CD4+ T cells were stim-
ulated with either α-CD3/α-CD28-coatedplates or with irradiated CD4+ and CD8+ depleted
Thy1.2+ BALB/c splenocytes pulsed with TSaa57-74 (p7) at 2.5 μg/ml. Th1 biasing conditions
included 10 ng/ml recombinant mouse IL-12 (Genetics Institute, Cambridge,MA) and 10 μg/
ml anti-IL-4 neutralizingmAb 11B11 (NCI Biological Resources Branch, Frederick,MD).
Th17 biasing conditions included 1 ng/ml recombinant human TGF-β (Biolegend, San Diego,
CA), 50 ng/ml recombinant mouse IL-6 (Invitrogen, Carlsbad, CA), 20 ng/ml recombinant
mouse IL-23 (R&D Systems, Minneapolis, MN), 10 μg/ml anti-IL-4 (NCI Biological Resources
Branch), and 10 μg/ml anti-IFN-γ neutralizingmAb XMG1.2 (BD Pharmingen, San Diego,
CA). Every 3 days, Th1 cell cultures received 10 U/ml IL-2 while Th17 cell cultures received 20
ng/ml IL-23. Cells were stimulated again 1 week later in the presence of the same biasing cyto-
kines and antibodies. IL-2 or IL-23 was again added 3 days after the second stimulation. Th1
and Th17 cells were used one week after the second stimulation. Polyclonal Th17 cells were
generated similarly using wild-typeCD4+ T cells; on days 0 and 7, these cells were stimulated
with immature DCs pulsed with the supernatants of repeatedly freeze-thawedT. cruzi trypo-
mastigotes. IL-17+ cell purification was performed usingMiltenyi IL-17 cell secretion purifica-
tion kits according to manufacturer instructions.
Adoptive transfers and assessment of protective immunity
In vitro generated Th1 or Th17 cells were transferred i.v. into RAG KO mice, along with poly-
clonal CD8+ T cells purified from naïve BALB/c mice by positive selection using α-CD8
microbeads (Miltenyi Biotec, Auburn, CA). RAG KO mice received 0.5–2 x 106 Th1 or Th17
cells, and 3–5 x 106 CD8 T cells, by tail vein injection and were challenged s.c. one day later
with 5,000 CMT. Parasitemia was measured post-infectionmicroscopically using 1.5 μl periph-
eral blood taken from the tip of the tail. Protection was also assessed by survival of infected
mice. At 3, 6, 7 and 10 days post-infection, the spleens from representative mice were harvested
for immune studies.
In vivo IL-17A neutralization
CD8+ T cells were transferred along with TS-CD4-Tg Th17 cells into RAG KO mice that were
infected s.c. the following day with 5,000 T. cruziCMT. In order to neutralize IL-17A, mice
were injected intraperitoneally (i.p.) with 100 μg of either anti-mouse IL-17A mAb (clone
17F3) or mouse IgG1 isotype control (clone MOPC-21), both from Bio X Cell (West Lebanon,
NH). Mice were injectedwith antibodies every 48 hours, beginning 1 day before infection and
continuing for 30 days post infection.
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IL-17A adenovirus
A recombinant adenovirus expressing murine IL-17A was originally described by Schwarzen-
berger et al. [41] and generously provided by Dr. Shabaana Khader (Washington University,
Saint Louis,MO). A control recombinant adenovirus (Ad5) expressing β-galactosidase (β-gal)
was also used [42,43]. Viruses were propagated in HEK-293A cells at Saint Louis University
using endotoxin-free conditions, purified by CsCl as previously described [44], and stored at
-80°C in 20mM Tris (pH 8) with 4% sucrose. RAG KO mice were injected i.v. with 5x109 PFU
of recombinant adenovirus encoding either mIL-17A (IL-17A AdV) or β-gal (ctrl AdV) one
day prior to infection and 7 days post-infection.Mice also received CD8+ T cells i.v. and were
challenged s.c. with 5,000 T. cruziCMT. IL-17A was measured in the serum of infectedmice
by ELISA according to the manufacturer’s instructions (BioLegend, San Diego, CA).
Flow cytometry and intracellular cytokine staining
Cell surface staining was performed according to standard procedures using antibodies against
murine CD3, CD8, CD4, CD19, CD44 and Thy1.1 (CD90.1), all purchased from BD Pharmin-
gen (San Diego, CA). For intracellular staining, monoclonal antibodies against IFN-γ (BD
Pharmingen), IL-17A, IL-17F, MIP-1α, RORγt and T-bet (eBioscience, San Diego, CA) were
used. For intracellular staining of in vitro cultures, cells were restimulated with phorbol-
12-myristate 13-acetate (PMA, 10 ng/ml) and ionomycin (500 ng/ml) for 3 hours. For intracel-
lular staining of spleen cells post-infection, cells were restimulated ex vivowith A20-TS for 6
hours. All intracellular stained cells were cultured with monensin (GolgiPlug, 1 μl/ml) and bre-
feldin A (GolgiStop, 0.67 μl/ml) for the last 3 hours of stimulation at 37°C (both from BD Phar-
mingen). After surface staining, cells were fixed and permeabilizedwith Foxp3/Transcription
Factor Staining Buffer Set (eBioscience) before intracellular staining, according to manufactur-
er’s instructions. Cells were analyzed with a BD LSR II flow cytometer and FlowJo v7 software
(Tree Star, Inc.).
In vitro protection assays
To generate peritoneal exudate macrophages (PEM), BALB/c mice were injected i.p. with
100 μg Concanavalin A (Sigma Aldrich, Saint Louis,MO). Four days later, PEM were harvested
from the peritoneal cavity of these mice and plated in 8-well tissue culture slide chambers
(Nunc LabTek from Thermo Scientific,Waltham, MA) at 1.25x106 cells/well in DMEMwith
10% FBS. After 2–5 hours, nonadherent cells were washed away and PEMwere infected with
T. cruzi CMT at an MOI of 5 (6.25x106 parasites/well) for 3 hours. Extracellular parasites were
then washed away and TS-CD4-Tg Th1 or Th17 cells added at a macrophage to T cell ratio of
25:1 (5x104 cells/well). Two days later, slide chambers were removed from slides, and slides
were washed, dried, fixed and stained with a modifiedWright Giemsa stain, Diff-Quik (IMEB,
Inc., San Marcos, CA). The number of infectedmacrophages was determinedmicroscopically.
Variations of this assay included using neutralizing antibodies against IFN-γ (clone XMG1.2,
BD Pharmingen) or IL-17A (clone TC11-18H10, BD Pharmingen) at 10 μg/ml, using the puri-
fied cytokinesmIFN-γ (1000 U/ml, Genentech, San Francisco, CA) or recombinant mouse IL-
17A (100 ng/ml, R&D Systems) instead of T cells, and inhibiting inducible nitric oxide synthase
(iNOS) with N6-(1-Iminoethyl)-L-lysine (L-NIL, 1mM, Sigma Aldrich, Saint Louis, MO).
Supernatants from the infectedmacrophage cultures were collected 24 and 48 hours post infec-
tion. Nitric oxide concentration was estimated by measuring nitrite concentration in superna-
tants with the Griess reagent system according to the manufacturer’s instructions (Promega,
Fitchburg, WI).
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For experiments with bonemarrow-derivedmacrophages (BMDM), bonemarrow was har-
vested from the femurs and tibiae from C57BL/6WTOR C57BL/6 gp91phox KO mice. Cells
were cultured on 96-well and 6-well plates with 20 ng/ml recombinant mouseM-CSF (Pepro-
Tech, Rocky Hill, NJ) in DMEMwith 10% FBS for 7 days. BMDMwere then removed from
culture plates with CellStripper non-enzymatic dissociation reagent (Corning, Corning,NY),
transferred to 8-well slide chambers at 2x105 cells/well, and infected with CMT at MOI of 10.
Three hours post infection, extracellular parasites were washed away and either IFN-γ or IL-
17A was added. Two days later, slides were washed, dried, fixed and stained as described above.
CD8+ T cell in vitro activation assay
Polyclonal CD8+ T cells were purified from naïve BALB/c mice by positive selectionwith α-
CD8 microbeads (Miltenyi Biotec), labeled with the cell-staining dye CFSE (Invitrogen) and
stimulated with a suboptimal dose of plate-bound α-CD3 antibody (1 μg/ml, clone 145-2C11,
BD Biosciences) in 96-well plates with 2x105 cells/well. Further activation/co-stimulation was
provided by DCs (purified from spleens with α-CD11c microbeads,Miltenyi Biotec) and/or
TS-CD4-Tg Th1/Th17 cells (1x105 cells/well). Cellular responses were analyzed 5 days post-
activation by re-stimulating with PMA and ionomycin and analyzing by flow cytometry to
measure proliferation (by CFSE dilution), CD44 surface expression, and production of IFN-γ
and MIP-1α. Additional modifications of this assay included using supernatants from activated
Th1 or Th17 cells with or without a neutralizing antibody directed against IL-17A at 10 μg/ml
(BD Pharmingen). CD8+ T cells were also activated with supernatants by purified recombinant
mouse IL-17A, IL-17F, IL-21, IL-22 or GM-CSF at 100 ng/ml (all from R&D) instead of by co-
culture with CD4+ T cells. Results are presented as either frequency of CD8+ T cells positive for
the indicated activation marker or as fold increase as compared to that with α-CD3 activation
alone. IL-21 concentration in supernatants was measured by ELISA according to manufactur-
er’s instructions (eBioscience).
Enzyme-linked immunospot (ELISPOT) assay
Millititer HA 96-well microtiter plates with nitrocellulose bases (Millipore, Bedford,MA) were
coated with 10 μg/ml of either murine anti-IFN-γmAb (clone R46A2, BD Pharmingen, San
Diego, CA) or anti-IL-17A mAb (clone TC11-18H10, BD Pharmingen) overnight at 4°C. Plates
were washed with PBS 4 times and blocked with RPMI + 10% FBS at room temperature (RT)
for at least 2 hours. Total spleen cells from infected RAG KO mice, spleen cells from immunized
BALB/c mice, CD4+ T cell clones or peripheral bloodmononuclear cells (PBMCs) from
TS-CD4-Tgmice (1-3x105 cells/well) were stimulated with negative control A20 cells (NC
A20), stably TS-transfectedA20 cells (TS A20), A20 cells pulsed with TS p7 (KVTERWHSFRL-
PALVNV at 2.5 μg/ml; A20 + p7) or A20 cells pulsed with other overlapping peptides (at
2 μM). Some ELISPOT assays included stimulations of Tg cells with peritoneal exudate macro-
phages infectedwith T. cruzi. Additional stimulations were done with L-cells transfected with
I-Ad or I-Ed molecules (courtesy of Dr. Ron Germain, NIH). Numbers of IFN-γ- or IL-17A-pro-
ducing cells were detectedwith biotinylated anti-IFN-γAb (clone XMG, BD Pharmingen) or
anti-IL-17A (clone TC11-8H4, BD Biosciences), streptavidin conjugated to horseradish peroxi-
dase (HRP) (Jackson Immunoresearch Laboratories,West Grove, PA) and 3-amino-9-ethylcar-
bazole substrate precipitation. Results are reported as number of spot-forming cells (SFCs).
T. cruzi TS-specific IgG serum ELISA
Nunc Maxisorp flat-bottom 96-well plates (eBioscience)were coated with 5 μg/ml of recombi-
nant trans-sialidase protein at 4°C overnight. Plates were washed with PBS-T and blocked with
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10% FBS at room temperature, then mouse serum samples serially diluted in PBS were added
to wells and incubated overnight. Plates were washed and incubated with an anti-mouse IgG
antibody conjugated to horse radish peroxidase to detect TS-specific antibodies. Plates were
developedwith TMB substrate, and the reaction was stopped with H2SO4. Plates were analyzed
at 450 nm with a reference of 540 nm, and endpoint titers were determined as OD readings
above the highest ODmeasured for uninfected controls.
Statistics
Statistical analyses were performed using Prism v4 software (GraphPad Software, Inc., La Jolla,
CA). Mann-Whitney U tests or unpaired Student t tests were used to compare responses
between groups. Log-rank (Mantel-Cox) and Gehan-Breslow-Wilcoxon tests were used to
compare survival between groups. All data are presented with standard errors, ranges or scatter
plots to allow easy assessment of the variation.
Supporting Information
S1 Fig. Identification of an immunodominant trans-sialidaseMHC-II-restrictedT cell epi-
tope. Previous reports indicated the presence of CD4 epitopes within the N-terminal region of
the TS catalytic domain (aa33-275) [45]. (A-C). We designed and synthesized 57 overlapping
18mers spanning this region with 14 amino acid overlaps (see S1 Table). Spleen cells from con-
trol (A), DNA-TS intramuscularly (i.m.) (B) or CpG-rTS intranasally (i.n.) (C) vaccinated
mice were mixed with APCs pulsed with individual peptides and added to IFN-γ ELISPOT
wells. Peptide #7 (TSaa57-74, KVTERVVHSFRLPALVNV) consistently induced IFN-γ pro-
duction in T cells from TS DNA and CpG-rTS vaccinated mice (B-C). (D) To identify the
restriction element of p7, we prepared TS-specificCD4+ T cell lines from DNA-TS vaccinated
mice. L cells transfected with various MHC elements (I-Ad, I-Ed, or AβEαd) were pulsed with
p7 and mixed with TS-specificCD4+ T cells in IFN-γ ELISPOT assays. p7 is restricted by I-Ad.
(E) APCs pulsed with different doses of p7 (0.01–10μg/ml) demonstrate high avidity of peptide
binding to MHC. (F) Presentation of this peptide during T. cruzi infection is shown, where TS-
specific CD4+ T cells were stimulated with macrophages (PEMs) pulsed with p7 or infected
with T. cruzi parasites in overnight IFN-γ ELISPOT assays.
(TIF)
S2 Fig. TCR Tg CD4+ T cells specific for p7, a newly discoveredTrypanosoma cruzi trans-
sialidase epitope, help induce protective immunity. (A) Schematic model of TS and positions
of immunogenic CD4 p7 and CD8 TSKd1 epitopes. (B) Survival results of BALB/c mice (>5/
group) challenged with T. cruzi trypomastigotes after vaccination with DC pulsed with the
CD4 p7 and/or the CD8 TSKd1 peptide. Vaccination with both peptides was significantly
more protective than vaccination with either peptide alone (p<0.05 by both two-tailed Fisher
exact test and Kaplan-Meier analysis). (C) Schematic of T. cruzi p7-specific TCR transgenic
(TS-CD4-Tg)mice generation. (D) T cells from TS-CD4-Tgmice responded in IFN-γ ELI-
SPOT assays to APCs (A20 cells) either transfected with TS (TS A20) or pulsed with p7 peptide
(A20 + p7). (E-F) CFSE-labeled T. cruzi p7-specific TCR Tg CD4+ T cells were transferred i.v.
into naïve congenic BALB/c mice and activated in vivo by TS DNA intramusculary or 5,000 T.
cruzi trypomastigotes subcutaneously twice one week apart. Representative Flow Cytometry
plots depicting the frequency of Thy1.1+ CD4+ Tg T cells (E) and the absolute number of pro-
liferating Tg spleen cells (F) 3 days after the second stimulation are shown.
(TIF)
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S3 Fig. Generation of T. cruzi-specificTh1 and Th17 cells. (A) A schematic of the protocol
for generation of Th1 and Th17 cells is shown. Splenic CD4+ T cells from TS-CD4-Tgmice
were purified by positive selection and stimulated with either α-CD3/α-CD28-coatedplates or
with irradiated splenocytes depleted of CD4+ and CD8+ cells and pulsed with p7. The T cell
cultures were biased for Th1 responses with 10 ng/ml IL-12 and 10 μg/ml α-IL-4, and for Th17
responses with 1 ng/ml TGF-β, 50 ng/ml IL-6, 20 ng/ml IL-23, 10 μg/ml α -IL-4, and 10 μg/ml
α-IFN-γ. Every 3 days, Th1 cell cultures received 10 U/ml IL-2 while Th17 cell cultures
received 20 ng/ml IL-23. Cells were re-stimulated 1 week later in the presence of the same bias-
ing cytokines and antibodies and used one week after the second stimulation. (B-C) ICS of Th1
and Th17 cells showing production of IFN-γ and IL-17A. (D-E) ICS of Th1 and Th17 cells
showing expression of the transcription factors T-bet and RORγt. (F) IL-21 was produced by
RORγt+, IL-17A+ cells among the CD4+ T cells cultured under Th17-skewing conditions.
(TIF)
S4 Fig. Adoptively transferredTh17 cells retain IL-17-producing capabilities post-infec-
tion. Th1 or Th17 cells were co-transferred with polyclonal CD8+ T cells into RAG KO mice
prior to T. cruzi infection. 3, 6 and 10 days post-infection, spleen cells were harvested and the
CD4+ T cell responses were studied. (A-B) Total spleen cells were restimulated ex vivowith TS
A20 antigen presenting cells for 6 hours and analyzed by intracellular cytokine staining for
IFN-γ (A) and IL-17A (B). Shown are the frequencies of TS-specific, cytokine-producing cells
as a percentage of CD4+ T cells. (C-D) Total spleen cells were restimulated ex vivowith A20
cells pulsed with p7 overnight in ELISOT assays to identify IFN-γ-producing (C) or IL-17A-
producing cells (D) Shown is the number of p7-specific spot forming cells per million total
spleen cells after subtracting background (SFC to negative control A20 cells). Similar results
were seen in multiple experiments.
(TIF)
S5 Fig. Purified IL-17+ Th17 cells protect against T. cruzi. (A) More than 90% of cells cap-
tured using purification kits expressed IL-17, indicating high purity. (B) The persistence of
adoptively transferred Th17 cells could be detected among spleen cells recovered frommice
receiving either total Th17 cell cultures or purified IL-17+ T cells more than one week later, as
indicated by spots formed on IL-17 ELISPOT in response to p7, the cognate epitope for the
TCR transgenic T cells. (C) Similar levels of IFN-γwere produced by spleen cells upon stimula-
tion with TS betweenmice receiving either total Th17 cells or purified IL-17+ Th17 cells, indi-
cating similar immune activation. (D). Mice receiving purified IL-17+ Th17 cells controlled
infection as well as mice receiving total Th17 biased cells, as indicated by similar blood parasite
burden. (E) Co-transfer of purified IL-17+ Th17 cells protected mice frommortality following
T. cruzi challenge.
(TIF)
S6 Fig. Polyclonal parasite-specificTh17 cells generated fromwild-typeCD4+ T cells confer
significant protection against T. cruzi-infection. (A) Polyclonal parasite-specific Th17 cells
can be generated by co-culturingwild-typeCD4+ T cells with dendritic cells pulsed with whole
T. cruzi parasite lysate antigens twice, one week apart under Th17-skewing conditions, as indi-
cated by TS antigen-specific IL-17A secretion in ELISPOT assays at week 2. (B) PurifiedCD8+
T cells recovered from RAG KO mice co-adoptively transferred with polyclonal, parasite-spe-
cific Th17 cells exhibit increased expression of activation markers, including IFN-γ, T-bet, and
CD44, compared to RAG KO mice not receiving co-adoptive transfer of polyclonal Th17 cells,
as measured by ICS assay. (C) Co-adoptive transfer of polyclonal Th17 cells with CD8+ T cells
results in improved control of parasitemia at day 18 compared to mice receiving CD8+ T cells
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alone or no T cell transfer. (D). As seen with transgenic, T. cruzi-specificTh17 cells, polyclonal
Th17 cells also confer 100% long-term protection from T. cruzi-related mortality.
(TIF)
S7 Fig. T. cruzi-specificT-bet KO Th17 cells confer protection similar to WTTh17 cells.
(A) A small population of Tg CD4+ T cells cultured under Th17-biasing conditions expressed
IFN-γ. T-bet KO Tg Th17 cells are unable to produce IFN-γ, as confirmed by ICS assays. (B)
ICS analysis of cells recovered frommice up to 101 days after infection and stimulated ex vivo
with TS A20 cells demonstrates that T-bet KO Th17 cells do not regain IFN-γ-producing capa-
bilities in vivo. (C) Parasitemia measured up to 101 days post-infection indicated that protec-
tion by T-bet KO Tg Th17 cells was comparable to that of WT Th17 cells and was maintained
long-term.
(TIF)
S8 Fig. (A) Intramuscular vaccination of TCR Tg mice with recombinant TS protein (rTS)
induces antigen-specific Th1 cells, detectable by IFN-γ ELISPOT, when the TLR-9 agonist
CpG is added as an adjuvant, but not the TLR-1/2 agonist Pam3CSK4. (B) Antigen-specific
Th17 cells, detectable by IL-17A ELISPOT assay, develop in mice vaccinated with rTS and
Pam3CSK4, but not mice vaccinated with rTS and CpG. The induction of Th17 cells by vacci-
nation with rTS and Pam3CSK4 is increased in T-bet KO TCR Tg mice. Shown are responses
to A20 TS cells with background subtracted (SFC to negative control A20 cells).
(TIF)
S1 Table. TS peptide amino acid sequences used in ELISPOT assays in S1 Fig.
(TIF)
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